Malignant hyperthermia synonyms

Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle, primarily known by its official clinical name rather than a wide array of synonyms. While historical terms like "anesthesia-induced hyperpyrexia" exist, medical professionals now exclusively use Malignant hyperthermia (abbreviated as MH) to ensure clear communication during surgical and emergency care.

What are the historical and alternative names for Malignant hyperthermia?

In contemporary medical practice, Malignant hyperthermia is the universal standard term. However, patients may encounter older terminology in retrospective clinical literature or archived medical records. Historically, because the condition was first observed during the administration of volatile anesthetic gases, it was often referred to as "anesthesia-induced hyperpyrexia" or "malignant hyperpyrexia." Occasionally, you may see it described as "halothane-induced hyperpyrexia" in older studies, reflecting the specific anesthetic agents that were most commonly associated with triggering the reaction in the mid-20th century. These terms are largely considered historical and are no longer used in modern clinical settings to describe Malignant hyperthermia.

How is the condition classified in medical systems?

Official medical classification systems provide consistency for researchers and clinicians globally. In the International Classification of Diseases (ICD-10 and ICD-11), Malignant hyperthermia is consistently indexed under codes related to adverse effects of anesthesia. In the Online Mendelian Inheritance in Man (OMIM) database, which catalogs genetic conditions, it is listed as "Malignant Hyperthermia, Susceptibility To" (OMIM #145600), reflecting that the underlying genetic predisposition—most commonly linked to the RYR1 gene—is the core of the condition. Orphanet, the reference portal for rare diseases, uses the primary designation Malignant hyperthermia, ensuring that patients and doctors use a unified term when searching for clinical trials or specialized care.

Why does Malignant hyperthermia have different naming conventions?

The evolution of the name Malignant hyperthermia reflects our growing understanding of the pathology. Early naming focused on the clinical symptom (fever, or "hyperpyrexia") observed in the operating room. As medical science advanced, it became clear that the fever was a secondary symptom of a deeper, underlying pharmacogenetic defect in skeletal muscle calcium regulation. The shift away from "hyperpyrexia" to "hyperthermia" helped clinicians distinguish the condition from other causes of high fever, such as infection or neuroleptic malignant syndrome. Today, Malignant hyperthermia is the preferred term because it accurately describes the physiological state induced by volatile anesthetics or succinylcholine in susceptible individuals.

Key facts regarding the nomenclature and identification of the condition

• Preferred Term: Malignant hyperthermia (MH).


• Common Abbreviation: MH.


• Genetic Designation: Often referred to as "RYR1-related myopathy" in specific genetic contexts, though this is a broader category than MH alone.


• International Recognition: Orphanet ID ORPHA:423.


• Community Insight: At DiseaseMaps.org, 42 people with Malignant hyperthermia have connected to share their experiences and navigate medical records using these standardized terms.

Next steps

• If you suspect you have a personal or family history of Malignant hyperthermia, request a consultation with a specialized anesthesiologist or a clinical geneticist.


• Ensure your medical records clearly state your status to prevent the use of triggering anesthetic agents during future surgeries.


• Carry a medical alert identification card or bracelet specifying your susceptibility to Malignant hyperthermia.


• Join the DiseaseMaps.org community to connect with others who have successfully navigated the complexities of this condition.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Malignant hyperthermia (ORPHA:423).


• NIH Genetic and Rare Diseases Information Center (GARD): Malignant hyperthermia.


• OMIM (Online Mendelian Inheritance in Man): #145600, Malignant Hyperthermia.


• Malignant Hyperthermia Association of the United States (MHAUS): Clinical guidelines and patient resources.